A Prospective, Single-Center, Open-Label, Study of the Plasma Pharmacokinetics and Safety Following Topical Administration of LNZ101 and LNZ100 Ophthalmic Solutions in Healthy Adult Subjects With Presbyopia
Latest Information Update: 18 Oct 2023
At a glance
- Drugs Aceclidine (Primary) ; Aceclidine/brimonidine (Primary)
- Indications Presbyopia
- Focus Pharmacokinetics
- Sponsors LENZ Therapeutics
Most Recent Events
- 12 Oct 2023 Status changed from recruiting to completed.
- 10 Jul 2023 New trial record
- 07 Jul 2023 Status changed from not yet recruiting to recruiting.